Results 91 to 100 of about 130,251 (209)
Gynecologic Oncology ReportsBackground: Treatment of recurrent chemotherapy, aromatase (AI) and MEK Inhibitor (MEKi) resistant low grade serous ovarian cancer (LGSOC) remains a challenge. Novel treatment options for KRAS mutated MEKi resistant LGSOC are warranted.
Victoria M. Ettorre +4 more
doaj +1 more source
Drug, Healthcare and Patient Safety, 2014 Jason J Luke, Patrick A Ott Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA Abstract: Development of selective inhibitors of BRAF has improved the survival of patients with BRAF-mutant melanoma.
Luke JJ, Ott PA
doaj
Scientific ReportsCysteine protease inhibitor 1 (CST1) is a cystatin superfamily protein that inhibits cysteine protease activity and is reported to be involved in the development of many malignancies.
Liangming Zhang +9 more
doaj +1 more source
Tumor-stroma interactions influence the response to PI3K targeted agents in preclinical models of colorectal cancer (CRC) [PDF]
, 2019 Introduction: One of the main obstacle to the successful development of therapeutic strategies remains the identification of biomarker underlying drug resistance. Recently, investigators have become more aware the role of the tumor microenvironment (TME)
Bazzichetto, Chiara
core
Dasatinib resensitizes BRAF/MEK inhibitor efficacy in patient-derived xenografts from patients with progression on BRAF/MEK inhibitor treatment. [PDF]
iScienceRebecca VW +26 more
europepmc +1 more source